Inebilizumab
Inebilizumab is a pharmaceutical drug with 18 clinical trials. Currently 11 active trials ongoing. Historical success rate of 100.0%.
Success Metrics
Based on 1 completed trials
Phase Distribution
Phase Distribution
0
Early Stage
8
Mid Stage
8
Late Stage
Highest Phase Reached
Phase 4Trial Status & Enrollment
50.0%
1 of 2 finished
50.0%
1 ended early
11
trials recruiting
18
all time
Detailed Status
Development Timeline
Analytics
Development Status
Trials by Phase
Trials by Status
Recent Activity
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
Clinical Trials (18)
A Phase 3 Study of Inebilizumab in Participants With Primary Membranous Nephropathy
Rituximab Versus Ravulizumab, Inebilizumab, Satralizumab, and Eculizumab in NMOSD
A Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety and Tolerability of Inebilizumab in Children With Generalized Myasthenia Gravis (gMG)
Study to Evaluate the Pharmacokinetics, Pharmacodynamics, Safety, and Tolerability of Inebilizumab in Pediatric Participants With IgG4-RD
A Phase 2 Master Protocol Assessing Inebilizumab and Blinatumomab in Autoimmune Diseases
A Trial of Inebilizumab in Participants With Autoimmune Hepatitis
CD19-B Cell Depletion in PAIS-ME/CFS Patients
Myasthenia Gravis Inebilizumab Trial
A Study of Inebilizumab Efficacy and Safety in IgG4- Related Disease
A Study of MT-0551 in Patients With Systemic Sclerosis
Study of Inebilizumab in Pediatric Subjects With Neuromyelitis Optica Spectrum Disorder
Long-term, Open-label, Safety Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorder (NMOSD)
The ExTINGUISH Trial of Inebilizumab in NMDAR Encephalitis
Inebilizumab in Acute Neuromyelitis Optica Spectrum Disorders
Safety and Tolerability of Inebilizumab, VIB4920, or the Combination in Highly Sensitized Candidates Awaiting Kidney Transplantation From a Deceased Donor
A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
Inebilizumab and Rituximab in Neuromyelitis Optica Spectrum Disorders
N-MOmentum: A Clinical Research Study of Inebilizumab in Neuromyelitis Optica Spectrum Disorders
All 18 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 18